Home » Stocks » Theravance Biopharma

Theravance Biopharma, Inc. (TBPH)

Stock Price: $16.92 USD 0.00 (0.00%)
Updated Aug 13, 2020 4:00 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.07B
Revenue (ttm) 76.80M
Net Income (ttm) -269.98M
Shares Out 63.52M
EPS (ttm) -4.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $16.92
Previous Close $16.92
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 16.60 - 17.43
Day's Volume 1,680
52-Week Range 15.72 - 31.54

More Stats

Market Cap 1.07B
Enterprise Value 1.29B
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 63.52M
Float 39.84M
EPS (basic) -4.62
EPS (diluted) -4.61
FCF / Share -3.53
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.41M
Short Ratio 8.18
Short % of Float 12.00%
Beta 1.36
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 13.99
PB Ratio n/a
Revenue 76.80M
Operating Income -280.43M
Net Income -269.98M
Free Cash Flow -222.12M
Net Cash -218.89M
Net Cash / Share -3.45
Gross Margin -189.90%
Operating Margin -365.16%
Profit Margin -351.60%
FCF Margin -289.23%
ROA -33.17%
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (10)

Buy 7
Overweight 0
Hold 2
Underweight 1
Sell 0

Analyst Consensus: Buy

Price Target

$31.80*
(87.94% upside)
Low
20.0
Current: $16.92
High
42.0
Target: 31.80
*Average 12-month price target from 10 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue73.4160.3715.3948.6542.1311.690.23130
Revenue Growth21.61%292.37%-68.37%15.48%260.42%5071.68%-99.83%-
Gross Profit73.4159.669.3645.7537.477.630.23130
Operating Income-252-239-260-180-182-233-156-9.58
Net Income-236-216-285-191-182-237-156-9.58
Shares Outstanding55.6153.9752.3544.7134.1531.7631.7431.74
Earnings Per Share-4.25-3.99-5.45-4.26-5.34-7.46-4.92-0.30
Operating Cash Flow-238-113-201-98.99-169-175-121-119
Capital Expenditures-3.17-7.22-2.41-2.14-2.65-3.11-2.73-2.59
Free Cash Flow-241-120-203-101-172-178-124-122
Cash & Equivalents2825063495021732550.830.00
Total Debt511454224223----
Net Cash / Debt-22951.761262791732550.830.00
Assets40956044163930033825.18-
Liabilities63361232628957.0547.9842.21-
Book Value-224-51.59115350243290-17.04-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Theravance Biopharma, Inc.
Country Cayman Islands
Employees 316
CEO Rick E. Winningham

Stock Information

Ticker Symbol TBPH
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TBPH

Description

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease. Its product portfolio also include TD-1473, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY ELLIPTA for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Mylan Ireland Limited, Janssen Biotech, Inc., Alfasigma S.p.A, Trek Therapeutics, PBC, and Takeda Pharmaceutical Company Limited. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.